Advanced pharmaceutical solutions
Targeted • Precise • Effective
Shilpa Medicare manufactures peptide APIs — including GLP-1 receptor agonists semaglutide and liraglutide — by solid-phase peptide synthesis at Raichur, with dedicated peptide capacity commissioning.
Shilpa Medicare manufactures peptide Active Pharmaceutical Ingredients using solid-phase peptide synthesis at its Raichur, Karnataka facilities, with a dedicated peptide manufacturing block under construction that will provide one of India's largest solid-phase synthesis capacities. The peptide portfolio includes GLP-1 receptor agonists — semaglutide and liraglutide — alongside octreotide, desmopressin and custom peptide programmes.
Peptide therapeutics have moved from niche to central. GLP-1 receptor agonists alone have reshaped the metabolic and obesity treatment landscape, and the coming patent cliff across major peptide products will create one of the largest generic opportunities of the decade.
Manufacturing peptides at commercial scale is a different discipline from small-molecule chemistry. It demands solid-phase synthesis capability, resin and reagent supply security, purification at scale, exacting impurity control and analytical methods capable of resolving closely-related peptide impurities. Capacity is the binding constraint industry-wide.
Shilpa Medicare has been building that capability inside its existing API infrastructure and is now commissioning dedicated peptide capacity.
Capability | Detail |
|---|---|
| Synthesis platforms | Solid-phase peptide synthesis (SPPS); hybrid SPPS/LPPS approaches for longer sequences |
| Backward integration | In-house manufacture of key starting materials, protected amino acid derivatives and side-chain building blocks — reducing external dependency and cost |
| Purification | Preparative chromatography at scale; lyophilisation |
| Analytical | Peptide-specific method development, related-substance profiling, peptide mapping, amino acid analysis, mass confirmation |
| Dedicated capacity | Dedicated peptide block under construction at Raichur, targeted to be among India's largest solid-phase synthesis capacities |
| Regulatory | Drug Master File filings in progress for GLP-1 molecules; existing CEPs held for octreotide and desmopressin |
Metabolic peptides at the center of the GLP-1 growth opportunity.
Regulatory-proven peptide APIs in commercial supply.
Through its 30.4% shareholding in Gate2Brain S.L. (Barcelona), Shilpa Medicare is associated with a peptide-shuttle platform designed to carry therapeutic payloads across the blood-brain barrier. The lead asset targets diffuse intrinsic pontine glioma and paediatric glioblastoma and holds Orphan Drug Designation from both the US FDA and the EMA. Shilpa Biocare serves as CMC, manufacturing and regulatory partner.
Shilpa Medicare offers peptide development and manufacture on a contract basis: route selection and synthesis strategy, process development and optimisation, impurity identification and control, analytical method development and validation, scale-up, validation batches, regulatory documentation and commercial supply. → Peptide CDMO services
